J Gen Virol Faster Access
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Gen Virol 65 (1984), 1675-1686; DOI 10.1099/0022-1317-65-10-1675
© 1984 Society for General Microbiology

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knoblich, A.
Right arrow Articles by Falke, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knoblich, A.
Right arrow Articles by Falke, D.
Agricola
Right arrow Articles by Knoblich, A.
Right arrow Articles by Falke, D.

Enhancement of Antibody Formation against Herpes Simplex Virus in Mice by the T-Cell Mitogen Bestatin

Andreas Knoblich, Werner E. G. Müller1, Veronika Harle-Grupp and Dietrich Falke

Institut für Medizinische Mikrobiologie, Abteilung für Experimentelle Virologie
and1 Institut für Physiologische Chemie, Abteilung ‘Angewandte Molekularbiologie’, Johannes-Gutenberg-Universität, 6500 Mainz, Federal Republic of Germany

The influence of the T-lymphocyte-stimulating dipeptide bestatin on the induction of neutralizing antibodies against herpes simplex virus type 1 in the mouse was investigated. dose—response experiments revealed two active ranges from 1 ng/kg to 100 ng/kg and from 10 µg/kg to 10 mg/kg or more. Bestatin (10 mg/kg) enhanced antibody levels after primary infection, if injected between day 5 and day 8 after infection with a maximum effect at day 5. Following secondary infections, bestatin was most effective at day 1 after secondary infection. Moreover, the antibody-generating potency of a formalinized herpes simplex virus type 1 vaccine was elevated considerably. Bestatin and silica seemed to be effective systemically. Treatment of mice with silica before virus infection and additionally with bestatin at day 1 after infection resulted in an additive effect on antibody production. Comparable effects could be obtained when polyinosinic acid·polycytidylic acid or indomethacin was combined with bestatin at day 1. It was assumed that certain factors released by macrophages ‘sensitize’ the antibody-producing system for the enhancing activity of bestatin at day 1. Indeed, culture fluids of macrophages obtained from mice either pretreated with silica or infected by herpes simplex virus were active in enhancing antibody formation upon injection into mice at day 1 in combination with bestatin. Bestatin did not induce interferon activity. No influence of bestatin on the virus content of organs or on mortality was observed.

Keywords: bestatin, HSV-1, antibody formation, immunopotentiation

Received 25 April 1984; accepted 27 June 1984.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL
J MED MICROBIOL ALL SGM JOURNALS
Copyright © 1984 by the Society for General Microbiology.